SCHEMBL21284642

SCHEMBL21284642

CCc1nc(-c2ccc3c(c2)CC[C@H]3NC(=O)OCCOC)no1

nearest known ligand 0.43

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.43
▸ TSHR P16473 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ HPGD P15428 1/20 0.42
▸ S1PR1 P21453 5/20 0.41
▸ SMPD1 P17405 2/20 0.41
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ POLB P06746 1/20 0.40
▸ BDKRB1 P46663 2/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21284635 0.91 ALDH1A1 (0.45) ALDH1A1TSHRHTTNPSR1HPGD
SCHEMBL21284735 0.88 S1PR1 (0.41) ALDH1A1TSHRHTTNPSR1S1PR1
SCHEMBL21284640 0.88 ALDH1A1 (0.42) ALDH1A1TSHRHTTNPSR1HPGD
SCHEMBL21284734 0.87 S1PR1 (0.43) ALDH1A1TSHRHTTNPSR1HPGD
SCHEMBL21284859 0.87 BDKRB1 (0.41) ALDH1A1TSHRHTTNPSR1HPGD
SCHEMBL21284754 0.86 ALDH1A1 (0.41) ALDH1A1TSHRHTTNPSR1HPGD
SCHEMBL21178567 0.85 BDKRB1 (0.50) ALDH1A1TSHRHTTNPSR1HPGD
SCHEMBL30961713 0.85 S1PR1 (0.40) ALDH1A1TSHRHTTNPSR1HPGD
SCHEMBL21178499 0.85 ALDH1A1 (0.48) ALDH1A1TSHRHTTNPSR1HPGD
SCHEMBL21270942 0.85 CA12 (0.47) ALDH1A1TSHRHTTNPSR1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3740481-B9 DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS CYTOKINETICS INC (US) 2024-10-23 — — EP claimed
EP-3740481-B1 DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS CYTOKINETICS INC (US) 2024-06-26 — — EP claimed
US-20250059173-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2025-02-20 — — US disclosed
US-12065436-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2024-08-20 — — US disclosed
US-20230119665-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2023-04-20 — — US disclosed
US-20230119665-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2023-04-20 — — US disclosed
US-11472796-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2022-10-18 — — US disclosed
US-20210147399-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2021-05-20 — — US disclosed
US-10836755-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2020-11-17 — — US disclosed
US-20190256504-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2019-08-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230119665-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, TNNT2, MYLK2 ALDH1A1 3390/4885TSHR 2655/4885HTT 3581/4885
US-10836755-B2 Cardiac sarcomere inhibitors TNNI3, TNNT2, MYLK2 ALDH1A1 3390/4885TSHR 2655/4885HTT 3581/4885
US-20210147399-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, TNNT2, MYLK2 ALDH1A1 3390/4885TSHR 2655/4885HTT 3581/4885
US-12065436-B2 Cardiac sarcomere inhibitors TNNI3, TNNT2, MYLK2 ALDH1A1 3390/4885TSHR 2655/4885HTT 3581/4885
US-11472796-B2 Cardiac sarcomere inhibitors TNNI3, TNNT2, MYLK2 ALDH1A1 3390/4885TSHR 2655/4885HTT 3581/4885
US-20190256504-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, TNNT2, MYLK2 ALDH1A1 3390/4885TSHR 2655/4885HTT 3581/4885
US-20250059173-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, TNNT2, MYLK2 ALDH1A1 3390/4885TSHR 2655/4885HTT 3581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback